Literature DB >> 7819689

Chronic childhood idiopathic thrombocytopenia purpura: long-term follow-up.

H Tamary1, C Kaplinsky, I Levy, I J Cohen, I Yaniv, B Stark, Y Goshen, R Zaizov.   

Abstract

An understanding of the natural history of childhood chronic idiopathic thrombocytopenia purpura (ITP) could contribute to a rational therapeutic approach to its treatment, which remains controversial. In our retrospective study of 92 children with ITP, 22 had a chronic course and were followed for 3-14 years (median 8.6 years). Treatment, when indicated, was individualized: 4 patients (18.2%) did not receive any treatment, 14 (63.6%) received steroids only, while 4 (18.2%) were treated with steroids and one of the following: high-dose gamma globulin (4 patients), splenectomy (2 patients) or immunosuppressive therapy (2 patients). During follow-up, 14 patients (63.6%) achieved complete remission, 5 (22.7%) partial remission and only 3 (13.5%) remained severely thrombocytopenic, with minimal bleeding tendency. Eleven patients (50%) responded to the initial prednisone course (1-5 mg/kg/day), but showed a marked decrease in platelet count when steroids were tapered off. In view of the high rates of complete and partial remission and the mild course of the few non-responding patients, it is suggested that with adequate supportive therapy, follow-up problems and fatalities can be kept to a minimum. We believe that aggressive therapy, such as splenectomy, should be reserved for the rare symptomatic and severely thrombocytopenic patient.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7819689     DOI: 10.1111/j.1651-2227.1994.tb13175.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  6 in total

Review 1.  [Chronic idiopathic thrombocytopenic purpura. Current therapy concept and introduction to pathophysiologic, clinical and diagnostic aspects].

Authors:  A Böcher; F G Hagmann; H Kreiter
Journal:  Med Klin (Munich)       Date:  1998-12-15

Review 2.  Immunthrombocytopenic purpura as a model for pathogenesis and treatment of autoimmunity.

Authors:  P Imbach; J Akatsuka; V Blanchette; A Burek-Kozlowska; J Bussel; G Gaedicke; A Gianella-Borradori; E Gugler; A Hirt; B Imholz
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

Review 3.  Idiopathic thrombocytopenic purpura.

Authors:  P H Bolton-Maggs
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

4.  Characterization of chronic idiopathic thrombocytopenic purpura in Japanese children: a retrospective multi-center study.

Authors:  Masaru Kubota; Souichi Adachi; Ikuya Usami; Masayuki Okada; Toshiyuki Kitoh; Mitsutaka Shiota; Yoshihiro Taniguchi; Akihiko Tanizawa; Mitsuhiko Nanbu; Keigo Hamahata; Hisanori Fujino; Kousaku Matsubara; Yoshihiro Wakazono; Tatsutoshi Nakahata
Journal:  Int J Hematol       Date:  2010-01-05       Impact factor: 2.490

Review 5.  The thrombocytopenic purpuras. Recognition and management.

Authors:  S Gillis
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

6.  Long-term results of laparoscopic splenectomy in pediatric chronic immune thrombocytopenic purpura.

Authors:  Dong Jin Kim; Jae Hee Chung
Journal:  Ann Surg Treat Res       Date:  2014-05-23       Impact factor: 1.859

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.